NIRSEVIMAB (BEYFORTUS) – *NEW* RSV MONOCLONAL ANTIBODY FOR CHILDREN

INDICATION & ACIP RECOMMENDATIONS	All infants aged 8 months or less entering or born during their 1st RSV season **OR** children aged 8-19 months at high risk* for severe RSV entering their 2nd RSV season
DOSE	**Entering 1st RSV season:** • **Less than 5kg:** 50mg/0.5mL prefilled syringe IM x 1 dose • **Greater than 5kg:** 100mg/1mL prefilled syringe IM x 1 dose **Entering 2nd RSV season at high risk*:** 200mg IM x 1 (given as 2 x 100mg/1mL injections) **High risk defined as: , American Indian or Alaska Native children, chronic lung disease of prematurity who require medical support any time during 6-month period before start of second RSV season, severe immunocompromise, cystic fibrosis who have either severe lung disease or weight-for-length < 10th percentile*
ADMINISTRATION	**Given intramuscularly (IM).** Can be given with other vaccines at the same time, however, should alternate injection sites and DO NOT mix vaccines together in same syringe
ADVERSE EFFECTS	Minimal (injection site reactions)
TIMING OF ADMINISTRATION	 *Recommendations for timing of administration in clinics:* **Birth Month** / **Timing** April, June, or August / October (at either 2, 4, or 6-month well baby visit) May, July, September / November (at either 2, 4, or 6-month well baby visit) *Note: above are recommendations only; any child eligible to receive nirsevimab may receive it during RSV season accordingly*
AVAILABILITY AND STORAGE	**Nirsevimab (Beyfortus®) will be available via the Vaccine For Children (VFC) program in mid-late October**. Needs to be stored in refrigerator (2-8° C).
AVAILABILITY @ VALLEY	**Inpatient:** Nirsevimab (Beyfortus®) will be given inpatient to newborns consented to receive the medication prior to discharge. **Primary Care:** Nirsevimab (Beyfortus®) will be available at all Valley Primary Care Clinics
ABRYSVO® INFORMATION RE: PREGNANT MOTHERS	Abrysvo® is a new adult RSV vaccine that can be given to pregnant moms between gestational weeks 32 – 36 weeks to help confer RSV immunity to newborns for ~6 months. **ACIP recommends pregnant moms receive Abrysvo® between September – January during gestational weeks 32 – 36 weeks.** If this occurs, newborns do NOT need to receive nirsevimab (Beyfortus®)** in addition. **Valley will not be carrying Abrysvo® at this time**. Please refer patients to retail pharmacies for vaccination. ***Exceptions to this giving nirsevimab (Beyfortus®) in addition to Abrysvo®: maternal vaccination occurred < 14 days prior to delivery, infants born < 34 weeks gestation, rare clinical scenarios (infants at increased risk for severe disease)*
ADDITIONAL CONSIDERATIONS RE: PALIVIZUMAB (SYNAGIS®)	• Children who receive nirsevimab (Beyfortus®) should NOT receive palivizumab (Synagis®) for the same RSV season • For children receiving < 5 doses of palivizumab (Synagis®), nirsevimab (Beyfortus®) should be given and palivizumab subsequently stopped after nirsevimab®

Created by: Kamal Sandhu, PharmD, BCPS – Clinical Pharmacy Manager | Last Edited: 10/2/2023